Paper Review Records
All Paper Review Records
30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Elevated DSG3 Expression Is Correlated With Lung Cancer Progression and Poor Prognosis
Jian Yang; Hongyuan Chen; Jiang Hong; Xiaowei WangShow moreShow less
1. Department of Nuclear Medicine Changhai Hospital Shanghai China; 2. Department of Pathology Changhai Hospital Shanghai China; 3. Department of Thoracic Surgery Changhai Hospital Shanghai ChinaShow moreShow less
Unveiling MLLT3: A Key Transcription Factor in ESCC Prognosis and Immune Infiltration
Shuolei Li; Yashu Zhang; Yongtao BaiShow moreShow less
1. Department of Pharmacy Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital Zhengzhou Henan China; 2. Phase I Clinical Research Center Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital Zhengzhou Henan China; 3. Henan Engineering Research Center for Tumor Precision Medicine and Comprehensive Evaluation, Henan Cancer Hospital Zhengzhou Henan China; 4. Henan Provincial Key Laboratory of Anticancer Drug Research, Henan Cancer Hospital Zhengzhou Henan China; 5. Department of Spleen Stomach and Liver Diseases, Zhengzhou Hospital of Traditional Chinese Medicine Zhengzhou Henan ChinaShow moreShow less
SF3A3 Promotes Hepatocellular Carcinoma Progression and Regulates Jagged 2–Notch 1 Signaling
Jing Yang; Luyang Liu; Yan Zhang; Guangwen ZhouShow moreShow less
1. Department of General Surgery Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China; 2. Department of General Visceral & Transplantation Surgery, Heidelberg University Hospital Heidelberg Baden‐Württemberg Germany; 3. Department of Oncology Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai ChinaShow moreShow less
Elevated UBE2L6 Expression Predicts Poor Prognosis and Is Associated With Fatty Acid Metabolic Remodeling in Esophageal Cancer
Miss Jiaxin Yao; Miss Lu Wen; Miss Jinyue Ma; Miss Rendan Zhang; Miss Xianhua Hu; Miss Chunyan Zhao; Mr Bo MuShow moreShow less
1. School of Basic Medicine and Forensic Medicine, Sichuan North Medical College Nanchong City China; 2. Department of Graduate Students Sichuan North Medical College Nanchong City China; 3. Key Laboratory of Medical Imaging of Sichuan Province, Sichuan North Medical College Nanchong City ChinaShow moreShow less
Fusion Detection in Microsecretory Adenocarcinoma and Mucoepidermoid Carcinoma Using Chromogenic RNA In Situ Hybridization: A Promising Alternative to DNA‐Based Fluorescence In‐Situ Hybridization
Doreen N. Palsgrove; Calvin Hosler; Lisa M. Rooper; Dequan Weston; Andrew Day; Justin A. Bishop; Richard C. WangShow moreShow less
1. Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA; 2. Medical School Louisiana State University Health Science Center New Orleans Louisiana USA; 3. Department of Pathology The Johns Hopkins Hospital Baltimore Maryland USA; 4. Department of Otolaryngology‐Head and Neck Surgery University of Texas Southwestern Medical Center Dallas Texas USA; 5. Department of Dermatology, University of Colorado Anschutz Medical Campus (CU AMC) School of Medicine Aurora Colorado USA; 6. University of Colorado Cancer Center Aurora Colorado USAShow moreShow less
USP4‐Mediated Deubiquitination of PTBP1 Promotes Glioma Progression and Radioresistance by Enhancing PHB2‐Dependent Mitophagy
Tao Liu; Qingyao Zhu; Linwei Li; Xiaoyan Li; Wei WangShow moreShow less
1. Department of Oncology, Henan Provincial People's Hospital Zhengzhou University People's Hospital, Henan University People's Hospital Zhengzhou ChinaShow moreShow less
FAQ
How long does MOLECULAR CARCINOGENESIS take to review a manuscript?
As of 2026-11-17, CrushSCI has 30 complete review records for MOLECULAR CARCINOGENESIS. The fastest paper went from submission to acceptance in 11 days (Fusion Detection in Microsecretory Adenocarcinoma and Mucoepidermoid Carcinoma Using Chromogenic RNA In Situ Hybridization: A Promising Alternative to DNA‐Based Fluorescence In‐Situ Hybridization, received 2026-08-24, accepted 2026-09-04); the slowest took 350 days. The average is 134.1 days and the median is 124 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
